View ValuationSam-A Pharm 将来の成長Future 基準チェック /06現在、 Sam-A Pharmの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Pharmaceuticals 収益成長21.3%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesNew Risk • May 21New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 13% Last year net profit margin: 21% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks Profit margins are more than 30% lower than last year (13% net profit margin). Market cap is less than US$100m (₩95.3b market cap, or US$63.3m).分析記事 • Apr 01We Think That There Are More Issues For Sam-A Pharm (KOSDAQ:009300) Than Just Sluggish EarningsSam-A Pharm. Co., Ltd's ( KOSDAQ:009300 ) recent weak earnings report didn't cause a big stock movement. We think that...お知らせ • Feb 28Sam-A Pharm. Co., Ltd, Annual General Meeting, Mar 27, 2026Sam-A Pharm. Co., Ltd, Annual General Meeting, Mar 27, 2026, at 09:01 Tokyo Standard Time. Location: seminar room, 49, donghwagongdan-ro, munmak-eup, gangwon-do, wonju South KoreaUpcoming Dividend • Dec 22Upcoming dividend of ₩800 per shareEligible shareholders must have bought the stock before 29 December 2025. Payment date: 28 April 2026. Payout ratio is a comfortable 37% and this is well supported by cash flows. Trailing yield: 4.9%. Within top quartile of South Korean dividend payers (3.6%). Higher than average of industry peers (0.8%).Reported Earnings • Nov 19Third quarter 2025 earnings released: ₩9.00 loss per share (vs ₩345 profit in 3Q 2024)Third quarter 2025 results: ₩9.00 loss per share (down from ₩345 profit in 3Q 2024). Revenue: ₩15.1b (down 28% from 3Q 2024). Net loss: ₩54.1m (down 103% from profit in 3Q 2024). Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth.Declared Dividend • Nov 08Dividend of ₩800 announcedDividend of ₩800 is the same as last year. Ex-date: 29th December 2025 Payment date: 28th April 2026 Dividend yield will be 4.8%, which is higher than the industry average of 1.1%. Sustainability & Growth Dividend is well covered by both earnings (32% earnings payout ratio) and cash flows (34% cash payout ratio). The dividend has increased by an average of 18% per year over the past 6 years and payments have been stable during that time. Earnings per share has grown by 21% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.お知らせ • Nov 07Sam-A Pharm. Co., Ltd announces Annual dividend, payable on April 28, 2026Sam-A Pharm. Co., Ltd announced Annual dividend of KRW 800.0000 per share payable on April 28, 2026, ex-date on December 29, 2025 and record date on December 31, 2025.Reported Earnings • May 20First quarter 2025 earnings released: EPS: ₩1,029 (vs ₩1,534 in 1Q 2024)First quarter 2025 results: EPS: ₩1,029 (down from ₩1,534 in 1Q 2024). Revenue: ₩24.5b (down 18% from 1Q 2024). Net income: ₩6.28b (down 33% from 1Q 2024). Profit margin: 26% (down from 31% in 1Q 2024). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.お知らせ • Mar 01Sam-A Pharm. Co., Ltd, Annual General Meeting, Mar 28, 2025Sam-A Pharm. Co., Ltd, Annual General Meeting, Mar 28, 2025, at 09:01 Tokyo Standard Time. Location: seminar room, 49, donghwagongdan-ro, munmak-eup, gangwon-do, wonju South KoreaUpcoming Dividend • Dec 20Upcoming dividend of ₩750 per shareEligible shareholders must have bought the stock before 27 December 2024. Payment date: 14 April 2025. Payout ratio is a comfortable 20% and this is well supported by cash flows. Trailing yield: 4.4%. Within top quartile of South Korean dividend payers (3.9%). Higher than average of industry peers (1.1%).分析記事 • Dec 06Take Care Before Jumping Onto Sam-A Pharm. Co., Ltd (KOSDAQ:009300) Even Though It's 26% CheaperThe Sam-A Pharm. Co., Ltd ( KOSDAQ:009300 ) share price has fared very poorly over the last month, falling by a...分析記事 • Nov 13Should You Be Adding Sam-A Pharm (KOSDAQ:009300) To Your Watchlist Today?The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...New Risk • Sep 17New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (13% average weekly change). Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Market cap is less than US$100m (₩130.9b market cap, or US$99.5m).New Risk • Sep 05New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩132.1b (US$99.0m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (13% average weekly change). Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Market cap is less than US$100m (₩132.1b market cap, or US$99.0m).分析記事 • Aug 25Earnings Working Against Sam-A Pharm. Co., Ltd's (KOSDAQ:009300) Share Price Following 34% DiveSam-A Pharm. Co., Ltd ( KOSDAQ:009300 ) shares have retraced a considerable 34% in the last month, reversing a fair...Valuation Update With 7 Day Price Move • Aug 20Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₩25,350, the stock trades at a trailing P/E ratio of 6.5x. Average trailing P/E is 14x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 69% over the past three years.分析記事 • Jul 11Sam-A Pharm. Co., Ltd's (KOSDAQ:009300) Price Is Right But Growth Is Lacking After Shares Rocket 32%Despite an already strong run, Sam-A Pharm. Co., Ltd ( KOSDAQ:009300 ) shares have been powering on, with a gain of 32...Valuation Update With 7 Day Price Move • Jul 10Investor sentiment improves as stock rises 25%After last week's 25% share price gain to ₩27,200, the stock trades at a trailing P/E ratio of 6.9x. Average trailing P/E is 14x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 82% over the past three years.Buy Or Sell Opportunity • Jul 01Now 25% overvalued after recent price riseOver the last 90 days, the stock has risen 35% to ₩22,000. The fair value is estimated to be ₩17,622, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 27% over the last 3 years. Meanwhile, the company has become profitable.分析記事 • Jun 21Should You Be Adding Sam-A Pharm (KOSDAQ:009300) To Your Watchlist Today?The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Valuation Update With 7 Day Price Move • Jun 21Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₩22,500, the stock trades at a trailing P/E ratio of 5.7x. Average trailing P/E is 13x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 47% over the past three years.Buy Or Sell Opportunity • Jun 20Now 28% overvalued after recent price riseOver the last 90 days, the stock has risen 36% to ₩22,500. The fair value is estimated to be ₩17,622, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 27% over the last 3 years. Meanwhile, the company has become profitable.New Risk • Jun 18New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 7.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (7.5% average weekly change). Market cap is less than US$100m (₩123.9b market cap, or US$89.7m).Buy Or Sell Opportunity • May 29Now 22% overvalued after recent price riseOver the last 90 days, the stock has risen 26% to ₩21,500. The fair value is estimated to be ₩17,622, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 27% over the last 3 years. Meanwhile, the company has become profitable.分析記事 • May 25Sam-A Pharm. Co., Ltd's (KOSDAQ:009300) Shares Bounce 26% But Its Business Still Trails The MarketThe Sam-A Pharm. Co., Ltd ( KOSDAQ:009300 ) share price has done very well over the last month, posting an excellent...Reported Earnings • May 18First quarter 2024 earnings released: EPS: ₩1,534 (vs ₩1,114 in 1Q 2023)First quarter 2024 results: EPS: ₩1,534 (up from ₩1,114 in 1Q 2023). Revenue: ₩30.0b (up 22% from 1Q 2023). Net income: ₩9.36b (up 38% from 1Q 2023). Profit margin: 31% (up from 28% in 1Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 82% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • May 13Investor sentiment improves as stock rises 20%After last week's 20% share price gain to ₩19,150, the stock trades at a trailing P/E ratio of 5.5x. Average trailing P/E is 18x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 32% over the past three years.Upcoming Dividend • Dec 20Upcoming dividend of ₩400 per share at 2.4% yieldEligible shareholders must have bought the stock before 27 December 2023. Payment date: 12 April 2024. Payout ratio is a comfortable 12% and this is well supported by cash flows. Trailing yield: 2.4%. Lower than top quartile of South Korean dividend payers (3.5%). Higher than average of industry peers (1.1%).Reported Earnings • Nov 19Third quarter 2023 earnings released: EPS: ₩668 (vs ₩676 in 3Q 2022)Third quarter 2023 results: EPS: ₩668 (down from ₩676 in 3Q 2022). Revenue: ₩22.1b (up 2.8% from 3Q 2022). Net income: ₩4.08b (down 1.2% from 3Q 2022). Profit margin: 18% (in line with 3Q 2022). Over the last 3 years on average, earnings per share has increased by 93% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.Reported Earnings • May 19First quarter 2023 earnings released: EPS: ₩1,114 (vs ₩521 in 1Q 2022)First quarter 2023 results: EPS: ₩1,114 (up from ₩521 in 1Q 2022). Revenue: ₩24.7b (up 28% from 1Q 2022). Net income: ₩6.80b (up 114% from 1Q 2022). Profit margin: 28% (up from 17% in 1Q 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 52% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth.Upcoming Dividend • Dec 21Upcoming dividend of ₩250 per shareEligible shareholders must have bought the stock before 28 December 2022. Payment date: 14 April 2023. Payout ratio is a comfortable 14% and this is well supported by cash flows. Trailing yield: 1.5%. Lower than top quartile of South Korean dividend payers (3.3%). Higher than average of industry peers (1.0%).Valuation Update With 7 Day Price Move • Dec 15Investor sentiment improved over the past weekAfter last week's 17% share price gain to ₩18,550, the stock trades at a trailing P/E ratio of 10.3x. Average trailing P/E is 20x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 22% over the past three years.Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Upcoming Dividend • Dec 22Upcoming dividend of ₩300 per shareEligible shareholders must have bought the stock before 29 December 2021. Payment date: 02 May 2022. The company is paying out more than 100% of its profits but is generating plenty of cash to support the dividend. Trailing yield: 1.6%. Lower than top quartile of South Korean dividend payers (2.4%). Higher than average of industry peers (0.8%).分析記事 • Apr 08Key Things To Consider Before Buying Sam-A Pharm. Co., Ltd (KOSDAQ:009300) For Its DividendToday we'll take a closer look at Sam-A Pharm. Co., Ltd ( KOSDAQ:009300 ) from a dividend investor's perspective...Is New 90 Day High Low • Mar 10New 90-day low: ₩14,500The company is down 16% from its price of ₩17,350 on 10 December 2020. The South Korean market is up 6.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 23% over the same period.分析記事 • Mar 04Is Sam-A Pharm (KOSDAQ:009300) A Risky Investment?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...分析記事 • Jan 28How Much Did Sam-A Pharm's(KOSDAQ:009300) Shareholders Earn From Share Price Movements Over The Last Three Years?As an investor its worth striving to ensure your overall portfolio beats the market average. But in any portfolio...Is New 90 Day High Low • Jan 15New 90-day low: ₩15,600The company is down 10.0% from its price of ₩17,350 on 16 October 2020. The South Korean market is up 32% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 20% over the same period.分析記事 • Dec 24Four Days Left To Buy Sam-A Pharm. Co., Ltd (KOSDAQ:009300) Before The Ex-Dividend DateIt looks like Sam-A Pharm. Co., Ltd ( KOSDAQ:009300 ) is about to go ex-dividend in the next 4 days. Investors can...分析記事 • Dec 07Sam-A Pharm. Co., Ltd (KOSDAQ:009300) Is Yielding 1.6% - But Is It A Buy?Is Sam-A Pharm. Co., Ltd ( KOSDAQ:009300 ) a good dividend stock? How can we tell? Dividend paying companies with...Reported Earnings • Dec 03Third quarter 2020 earnings released: ₩111 loss per shareThe company reported a poor third quarter result with weaker earnings, revenues and control over expenses. Third quarter 2020 results: Revenue: ₩12.2b (down 26% from 3Q 2019). Net loss: ₩675.4m (down 135% from profit in 3Q 2019).Is New 90 Day High Low • Oct 22New 90-day low: ₩16,300The company is down 16% from its price of ₩19,500 on 24 July 2020. The South Korean market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 2.0% over the same period. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Sam-A Pharm は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測KOSDAQ:A009300 - アナリストの将来予測と過去の財務データ ( )KRW Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/202670,9288,8877,8479,722N/A12/31/202577,79912,9408,99510,723N/A9/30/202576,65913,1879,40811,620N/A6/30/202582,51815,34414,62318,157N/A3/31/202590,12619,00016,07220,793N/A12/31/202495,58122,08018,84425,247N/A9/30/2024101,39322,76825,82732,527N/A6/30/2024102,55024,74424,65530,253N/A3/31/2024102,51123,93625,29430,074N/A12/31/202397,21121,37417,20420,760N/A9/30/202395,93120,33816,34218,144N/A6/30/202395,32420,38715,49215,844N/A3/31/202387,15915,53117,96717,536N/A12/31/202281,70011,91220,46519,604N/A9/30/202275,47911,02917,43115,629N/A6/30/202266,1727,52017,81716,940N/A3/31/202263,6387,00013,68312,874N/A12/31/202154,6663,39213,71712,943N/A9/30/202150,90717814,00513,670N/A6/30/202150,870-1,1159,1489,078N/A3/31/202148,548-1,6509,93710,177N/A12/31/202053,6531249,0569,408N/A9/30/202059,7753,39210,0049,389N/A6/30/202064,0255,98614,96814,092N/A3/31/202070,3469,12814,88913,867N/A12/31/201971,56010,197N/A13,221N/A9/30/201970,7159,807N/A14,334N/A12/31/201866,9478,801N/A12,755N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: A009300の予測収益成長が 貯蓄率 ( 3.1% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: A009300の収益がKR市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: A009300の収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: A009300の収益がKR市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: A009300の収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: A009300の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/10 09:40終値2026/06/10 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Sam-A Pharm. Co., Ltd 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
New Risk • May 21New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 13% Last year net profit margin: 21% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks Profit margins are more than 30% lower than last year (13% net profit margin). Market cap is less than US$100m (₩95.3b market cap, or US$63.3m).
分析記事 • Apr 01We Think That There Are More Issues For Sam-A Pharm (KOSDAQ:009300) Than Just Sluggish EarningsSam-A Pharm. Co., Ltd's ( KOSDAQ:009300 ) recent weak earnings report didn't cause a big stock movement. We think that...
お知らせ • Feb 28Sam-A Pharm. Co., Ltd, Annual General Meeting, Mar 27, 2026Sam-A Pharm. Co., Ltd, Annual General Meeting, Mar 27, 2026, at 09:01 Tokyo Standard Time. Location: seminar room, 49, donghwagongdan-ro, munmak-eup, gangwon-do, wonju South Korea
Upcoming Dividend • Dec 22Upcoming dividend of ₩800 per shareEligible shareholders must have bought the stock before 29 December 2025. Payment date: 28 April 2026. Payout ratio is a comfortable 37% and this is well supported by cash flows. Trailing yield: 4.9%. Within top quartile of South Korean dividend payers (3.6%). Higher than average of industry peers (0.8%).
Reported Earnings • Nov 19Third quarter 2025 earnings released: ₩9.00 loss per share (vs ₩345 profit in 3Q 2024)Third quarter 2025 results: ₩9.00 loss per share (down from ₩345 profit in 3Q 2024). Revenue: ₩15.1b (down 28% from 3Q 2024). Net loss: ₩54.1m (down 103% from profit in 3Q 2024). Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth.
Declared Dividend • Nov 08Dividend of ₩800 announcedDividend of ₩800 is the same as last year. Ex-date: 29th December 2025 Payment date: 28th April 2026 Dividend yield will be 4.8%, which is higher than the industry average of 1.1%. Sustainability & Growth Dividend is well covered by both earnings (32% earnings payout ratio) and cash flows (34% cash payout ratio). The dividend has increased by an average of 18% per year over the past 6 years and payments have been stable during that time. Earnings per share has grown by 21% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.
お知らせ • Nov 07Sam-A Pharm. Co., Ltd announces Annual dividend, payable on April 28, 2026Sam-A Pharm. Co., Ltd announced Annual dividend of KRW 800.0000 per share payable on April 28, 2026, ex-date on December 29, 2025 and record date on December 31, 2025.
Reported Earnings • May 20First quarter 2025 earnings released: EPS: ₩1,029 (vs ₩1,534 in 1Q 2024)First quarter 2025 results: EPS: ₩1,029 (down from ₩1,534 in 1Q 2024). Revenue: ₩24.5b (down 18% from 1Q 2024). Net income: ₩6.28b (down 33% from 1Q 2024). Profit margin: 26% (down from 31% in 1Q 2024). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.
お知らせ • Mar 01Sam-A Pharm. Co., Ltd, Annual General Meeting, Mar 28, 2025Sam-A Pharm. Co., Ltd, Annual General Meeting, Mar 28, 2025, at 09:01 Tokyo Standard Time. Location: seminar room, 49, donghwagongdan-ro, munmak-eup, gangwon-do, wonju South Korea
Upcoming Dividend • Dec 20Upcoming dividend of ₩750 per shareEligible shareholders must have bought the stock before 27 December 2024. Payment date: 14 April 2025. Payout ratio is a comfortable 20% and this is well supported by cash flows. Trailing yield: 4.4%. Within top quartile of South Korean dividend payers (3.9%). Higher than average of industry peers (1.1%).
分析記事 • Dec 06Take Care Before Jumping Onto Sam-A Pharm. Co., Ltd (KOSDAQ:009300) Even Though It's 26% CheaperThe Sam-A Pharm. Co., Ltd ( KOSDAQ:009300 ) share price has fared very poorly over the last month, falling by a...
分析記事 • Nov 13Should You Be Adding Sam-A Pharm (KOSDAQ:009300) To Your Watchlist Today?The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...
New Risk • Sep 17New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (13% average weekly change). Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Market cap is less than US$100m (₩130.9b market cap, or US$99.5m).
New Risk • Sep 05New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩132.1b (US$99.0m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (13% average weekly change). Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Market cap is less than US$100m (₩132.1b market cap, or US$99.0m).
分析記事 • Aug 25Earnings Working Against Sam-A Pharm. Co., Ltd's (KOSDAQ:009300) Share Price Following 34% DiveSam-A Pharm. Co., Ltd ( KOSDAQ:009300 ) shares have retraced a considerable 34% in the last month, reversing a fair...
Valuation Update With 7 Day Price Move • Aug 20Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₩25,350, the stock trades at a trailing P/E ratio of 6.5x. Average trailing P/E is 14x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 69% over the past three years.
分析記事 • Jul 11Sam-A Pharm. Co., Ltd's (KOSDAQ:009300) Price Is Right But Growth Is Lacking After Shares Rocket 32%Despite an already strong run, Sam-A Pharm. Co., Ltd ( KOSDAQ:009300 ) shares have been powering on, with a gain of 32...
Valuation Update With 7 Day Price Move • Jul 10Investor sentiment improves as stock rises 25%After last week's 25% share price gain to ₩27,200, the stock trades at a trailing P/E ratio of 6.9x. Average trailing P/E is 14x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 82% over the past three years.
Buy Or Sell Opportunity • Jul 01Now 25% overvalued after recent price riseOver the last 90 days, the stock has risen 35% to ₩22,000. The fair value is estimated to be ₩17,622, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 27% over the last 3 years. Meanwhile, the company has become profitable.
分析記事 • Jun 21Should You Be Adding Sam-A Pharm (KOSDAQ:009300) To Your Watchlist Today?The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...
Valuation Update With 7 Day Price Move • Jun 21Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₩22,500, the stock trades at a trailing P/E ratio of 5.7x. Average trailing P/E is 13x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 47% over the past three years.
Buy Or Sell Opportunity • Jun 20Now 28% overvalued after recent price riseOver the last 90 days, the stock has risen 36% to ₩22,500. The fair value is estimated to be ₩17,622, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 27% over the last 3 years. Meanwhile, the company has become profitable.
New Risk • Jun 18New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 7.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (7.5% average weekly change). Market cap is less than US$100m (₩123.9b market cap, or US$89.7m).
Buy Or Sell Opportunity • May 29Now 22% overvalued after recent price riseOver the last 90 days, the stock has risen 26% to ₩21,500. The fair value is estimated to be ₩17,622, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 27% over the last 3 years. Meanwhile, the company has become profitable.
分析記事 • May 25Sam-A Pharm. Co., Ltd's (KOSDAQ:009300) Shares Bounce 26% But Its Business Still Trails The MarketThe Sam-A Pharm. Co., Ltd ( KOSDAQ:009300 ) share price has done very well over the last month, posting an excellent...
Reported Earnings • May 18First quarter 2024 earnings released: EPS: ₩1,534 (vs ₩1,114 in 1Q 2023)First quarter 2024 results: EPS: ₩1,534 (up from ₩1,114 in 1Q 2023). Revenue: ₩30.0b (up 22% from 1Q 2023). Net income: ₩9.36b (up 38% from 1Q 2023). Profit margin: 31% (up from 28% in 1Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 82% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • May 13Investor sentiment improves as stock rises 20%After last week's 20% share price gain to ₩19,150, the stock trades at a trailing P/E ratio of 5.5x. Average trailing P/E is 18x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 32% over the past three years.
Upcoming Dividend • Dec 20Upcoming dividend of ₩400 per share at 2.4% yieldEligible shareholders must have bought the stock before 27 December 2023. Payment date: 12 April 2024. Payout ratio is a comfortable 12% and this is well supported by cash flows. Trailing yield: 2.4%. Lower than top quartile of South Korean dividend payers (3.5%). Higher than average of industry peers (1.1%).
Reported Earnings • Nov 19Third quarter 2023 earnings released: EPS: ₩668 (vs ₩676 in 3Q 2022)Third quarter 2023 results: EPS: ₩668 (down from ₩676 in 3Q 2022). Revenue: ₩22.1b (up 2.8% from 3Q 2022). Net income: ₩4.08b (down 1.2% from 3Q 2022). Profit margin: 18% (in line with 3Q 2022). Over the last 3 years on average, earnings per share has increased by 93% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.
Reported Earnings • May 19First quarter 2023 earnings released: EPS: ₩1,114 (vs ₩521 in 1Q 2022)First quarter 2023 results: EPS: ₩1,114 (up from ₩521 in 1Q 2022). Revenue: ₩24.7b (up 28% from 1Q 2022). Net income: ₩6.80b (up 114% from 1Q 2022). Profit margin: 28% (up from 17% in 1Q 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 52% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth.
Upcoming Dividend • Dec 21Upcoming dividend of ₩250 per shareEligible shareholders must have bought the stock before 28 December 2022. Payment date: 14 April 2023. Payout ratio is a comfortable 14% and this is well supported by cash flows. Trailing yield: 1.5%. Lower than top quartile of South Korean dividend payers (3.3%). Higher than average of industry peers (1.0%).
Valuation Update With 7 Day Price Move • Dec 15Investor sentiment improved over the past weekAfter last week's 17% share price gain to ₩18,550, the stock trades at a trailing P/E ratio of 10.3x. Average trailing P/E is 20x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 22% over the past three years.
Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Upcoming Dividend • Dec 22Upcoming dividend of ₩300 per shareEligible shareholders must have bought the stock before 29 December 2021. Payment date: 02 May 2022. The company is paying out more than 100% of its profits but is generating plenty of cash to support the dividend. Trailing yield: 1.6%. Lower than top quartile of South Korean dividend payers (2.4%). Higher than average of industry peers (0.8%).
分析記事 • Apr 08Key Things To Consider Before Buying Sam-A Pharm. Co., Ltd (KOSDAQ:009300) For Its DividendToday we'll take a closer look at Sam-A Pharm. Co., Ltd ( KOSDAQ:009300 ) from a dividend investor's perspective...
Is New 90 Day High Low • Mar 10New 90-day low: ₩14,500The company is down 16% from its price of ₩17,350 on 10 December 2020. The South Korean market is up 6.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 23% over the same period.
分析記事 • Mar 04Is Sam-A Pharm (KOSDAQ:009300) A Risky Investment?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
分析記事 • Jan 28How Much Did Sam-A Pharm's(KOSDAQ:009300) Shareholders Earn From Share Price Movements Over The Last Three Years?As an investor its worth striving to ensure your overall portfolio beats the market average. But in any portfolio...
Is New 90 Day High Low • Jan 15New 90-day low: ₩15,600The company is down 10.0% from its price of ₩17,350 on 16 October 2020. The South Korean market is up 32% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 20% over the same period.
分析記事 • Dec 24Four Days Left To Buy Sam-A Pharm. Co., Ltd (KOSDAQ:009300) Before The Ex-Dividend DateIt looks like Sam-A Pharm. Co., Ltd ( KOSDAQ:009300 ) is about to go ex-dividend in the next 4 days. Investors can...
分析記事 • Dec 07Sam-A Pharm. Co., Ltd (KOSDAQ:009300) Is Yielding 1.6% - But Is It A Buy?Is Sam-A Pharm. Co., Ltd ( KOSDAQ:009300 ) a good dividend stock? How can we tell? Dividend paying companies with...
Reported Earnings • Dec 03Third quarter 2020 earnings released: ₩111 loss per shareThe company reported a poor third quarter result with weaker earnings, revenues and control over expenses. Third quarter 2020 results: Revenue: ₩12.2b (down 26% from 3Q 2019). Net loss: ₩675.4m (down 135% from profit in 3Q 2019).
Is New 90 Day High Low • Oct 22New 90-day low: ₩16,300The company is down 16% from its price of ₩19,500 on 24 July 2020. The South Korean market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 2.0% over the same period.